Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632684 | 0.88 | HDAC6 (0.39) | HDAC6HDAC1CRBNNPSR1MAPT | |
| SCHEMBL632588 | 0.88 | HDAC6 (0.37) | HDAC6HDAC1CRBNNPSR1MAPT | |
| SCHEMBL634226 | 0.87 | HDAC6 (0.39) | HDAC6HDAC1CRBN | |
| SCHEMBL633959 | 0.86 | HDAC6 (0.38) | HDAC6HDAC1CRBN | |
| SCHEMBL634127 | 0.86 | HDAC6 (0.38) | HDAC6HDAC1CRBNNPSR1MAPT | |
| SCHEMBL633345 | 0.86 | HDAC6 (0.36) | HDAC6HDAC1CRBNMAPT | |
| SCHEMBL632597 | 0.82 | CRBN (0.39) | HDAC6HDAC1CRBNMAPT | |
| SCHEMBL633493 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1CRBN | |
| SCHEMBL632924 | 0.80 | CRBN (0.41) | HDAC6HDAC1CRBNMAPT | |
| SCHEMBL632708 | 0.79 | CRBN (0.39) | HDAC6HDAC1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, CYC1 | HDAC6 2593/4885HDAC1 1210/4885CRBN 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.